跳至主要内容
临床试验/ACTRN12620001084976
ACTRN12620001084976进行中(未招募)2 期

Efficacy of Intravaginal Combination Therapy of Acetic and Lactic Acid (ICTALA) in premenopausal women with Recurrent Vulvovaginal Candidiasis – A Randomised, Double blind Placebo Controlled Clinical Feasibility Trial

Griffith Univeristy0 个研究点目标入组 15 人开始时间: 2020年10月20日最近更新:
适应症

试验速览

阶段
2 期
状态
进行中(未招募)
发起方
入组人数
15

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional
分配方式
Randomised controlled trial
主要目的
Prevention
盲法
Blinded (masking used)

入排标准

年龄范围
18 Years 至 60 Years(—)
性别
Female

入选标准

  • 1.Premenopausal women
  • 2. In good health (no serious current illness or specified chronic diseases, see exclusion criteria)
  • 3.A history of RVVC defined as greater than or equal to 4 episodes of Vulvovaginal Candidiasis in a 12 months period as documented in patient medical records and case history, including at least one positive vaginal culture pathology report
  • 4. Have a Sobel symptom score <3 at enrolment
  • 5. Willing to answer questionnaires and comply with the study requirements.
  • 6. Have a menstrual cycle between 26 and 35 days
  • 7. Ability to apply intravaginal therapies
  • 8. Ability to collect vaginal swabs
  • 9. On stable medication(s) and/or Complementary medicines, other than excluded (see below), for greater than or equal to 2 months

排除标准

  • 1. Vaginal pH>4.5 at Eligibility screening
  • 2. Positive SavvyCheck at Eligibility screening
  • 3. Positive Human Chorionic gonadotropin (hCG) urinalysis test at screening (confirming pregnancy), currently pregnant and/or breastfeeding
  • 4. Intra uterine device (hormonal or coil, ring pessary)
  • 5. Women of child bearing potential who have not been using effective methods of contraception for 14 days prior to Baseline Appointment 1.
  • 6. Individuals who are diagnosed with a significant chronic disease, including kidney, liver, uterine and autoimmune disease, sexually transmitted infection (except latent Herpes simplex viruses -HSV1 and HSV2), uncontrolled Diabetes (Type 1 or Type 2, HbA1c >7.5%), vulvar or vaginal medical condition (other than RVVC), pelvic inflammatory disease, recurrent urinary tract infection
  • 7. Current cancer or a remission diagnosis in the last 12 months (Skin cancer excision without treatment not a basis for exclusion).
  • 8. Individuals taking any medication that addresses hormones including hormone replacement therapy (except the combined OCP), antiestrogens, aromatase inhibitors or any medication of a hormonal blocking nature associated with a breast cancer diagnosis
  • 9. Individuals taking HMG-CoA reductase inhibitors, antiretroviral or immunosuppressant medication.
  • 10. Individuals taking antifungal, antimicrobial or anti-inflammatory medications applied for a chronic health condition (which can not be ceased)
  • 11. Individuals using vaginal douches, taking probiotics (oral or vaginal), or complementary medicines for the management of VVC (Caprylic acid, Origanum vulgare: Oregano herb/oil, Hydrastis canadensis: Golden Seal, Saccharomyces cerevisiae, Handroanthus heptaphyllus:Pau D’arco, Allium sativum: Garlic, Pseudowintera colorata: Horopito) except for those willing and able to cease (if ceased allow a 3 week wash out)
  • 12. Individuals who have commenced a new pharmaceutical or complementary medication < 2 months ago (and not willing or able to cease)
  • 13. Known allergy to any of the ingredients in the formulation
  • 14. Individuals that have participated in another clinical trial in the last 30 days

研究者

发起方
Griffith Univeristy

相似试验